发明名称 |
COMBINATION OF RIBOCICLIB AND DABRAFENIB FOR TREATING OR PREVENTING CANCER |
摘要 |
The present disclosure relates to pharmaceutical combinations comprising a cyclin dependent kinase 4/6 (CDK4/6) inhibitor compound, (b) a B-Raf inhibitor compound, and optionally (c) an alpha-isoform specific phosphatidylinositol 3 -kinase (PI3K) inhibitor compound, for the treatment or prevention of cancer, as well as related pharmaceutical compositions, uses, and methods of treatment or prevention of cancer. |
申请公布号 |
WO2017037587(A1) |
申请公布日期 |
2017.03.09 |
申请号 |
WO2016IB55076 |
申请日期 |
2016.08.25 |
申请人 |
NOVARTIS AG;CAPONIGRO, Giordano;HORN-SPIROHN, Thomas;LEHAR, Joseph |
发明人 |
CAPONIGRO, Giordano;HORN-SPIROHN, Thomas;LEHAR, Joseph |
分类号 |
A61K31/4439;A61K31/506;A61K31/519;A61P35/00 |
主分类号 |
A61K31/4439 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|